MAGEA3 and neoplasm: The median survival days of rMMH-immunized mice treated with either HepG2 or A549 tumor cells was the longest among all groups (Fig. 5d, e and Table 1), strongly suggesting a survival-benefit effect of either MAGE1 or MAGE3 vaccination in mouse.